LSL Pharma FY26 Q2 net loss widens to C$2.3 million; revenue more than doubles to C$14.6 million vs FY25 Q2

PUBT · 1d ago
LSL Pharma FY26 Q2 net loss widens to C$2.3 million; revenue more than doubles to C$14.6 million vs FY25 Q2
  • LSL Pharma posted Q2 FY2026 revenue of CAD 14.6 million, more than doubled year over year, rising 19% from Q1.
  • Net loss widened to CAD 2.3 million; adjusted EBITDA slipped to CAD 0.4 million from CAD 0.7 million.
  • CMO revenue rose 31% to CAD 8.5 million, eye-care climbed 57% to CAD 1.2 million; private label delivered CAD 5 million.
  • Six-month revenue reached CAD 26.9 million, up 95%; net loss widened to CAD 5.1 million, adjusted EBITDA eased to CAD 0.9 million.
  • Launched three eye-drops; targeting a Steri-Med production ramp by end-September, remediation substantially complete by end-2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LSL Pharma Group Inc. published the original content used to generate this news brief via CNW (Ref. ID: 202608250700CANADANWCANADAPR_C7966) on August 25, 2026, and is solely responsible for the information contained therein.